Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Intestinal Neuroendocrine Tumor 1Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 2Lutetium-177 2Liquid Biopsy 2pentetreotide 1fluorodopa F 18 1copper dotatate CU-64 1Yttrium-90 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Single Photon Emission Computed Tomography Computed Tomography 1Resveratrol 1Respiratory Therapy 1Referral and Consultation 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Palliative Care 1Nutrition Assessment 1Needles 1Magnetic Resonance Spectroscopy 1Endoscopic Mucosal Resection 1Diet Therapy 1Data Collection 1Cryosurgery 1Control Groups 1Colectomy 1Betaine 190Y-octreotide, DOTA-Tyr(3)- 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neuroendocrine Tumors × Data Collection × Clear all
NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡